Also see: TI, Cubist Pharma: Analysts' New Ratings
Editor's Note: Green and red arrows refer to intraday stock price movement.
NEW YORK (
STOCK COMMENTS / EPS CHANGES
target raised at Deutsche to $450. Expect iPad 2 to continue to drive growth in the tablet market. Buy rating.
estimates, target raised at Benchmark. Shares of BP now seen reaching $70, according to Benchmark Company. Estimates also increased, given higher oil prices. Buy rating.
estimates upped at UBS through 2012, UBS said. Company is seeing solid trading volumes. Neutral rating and $318 price target.
target upped at Piper to $24. Pricing growth remains strong. Overweight rating.
numbers increased at Stifel. COF estimates were raised through 2012, Stifel Nicolaus said. Credit trends continue to improve. Buy rating and new $64 price target.
estimates reduced at Brean Murray through 2012, Brean Murray said. Company is leveraged to a disjointed market in Japan. Buy rating and $65 price target.
estimates, target raised at Keybanc. Shares of CR now seen reaching $58, according to Keybanc. Estimates also increased, following positive meetings with management. Buy rating.
estimates, target increased at Jefferies. DVA estimates were raised through 2012, Jefferies said. Recent Medicare news is positive for the industry. Hold rating and new $95 price target.
numbers boosted at Citigroup. Shares of EW now seen reaching $99, according to Citigroup. Estimates also upped, given positive Cohort trial results. Buy rating.
estimates lowered at Citigroup through 2013, Citigroup said. Company should continue to face margin pressure. Hold rating and $46 price target.
target lowered at Deutsche to $40, according to Deutsche Bank. Recent checks in Asia, suggest a soft PC market. Hold rating.
numbers boosted at UBS. Shares of ICE now seen reaching $150, according to UBS. Estimates also upped, given better volume and pricing trends. Buy rating.
estimates, target reduced at Canaccord. Shares of INTC now seen reaching $19, according to Canaccord Genuity. Estimates also cut, as PC production appears to be tracking below expectations. Hold rating.
target increased at UBS to $110, UBS said. Leviathan has better LNC potential. Buy rating.
estimates, target boosted at Piper. Shares of NFLX now seen reaching $280, according to Piper Jaffray. Estimates also upped, given the company's international growth potential. Overweight rating.
numbers lowered at UBS. Shares of RFMD now seen reaching $7, according to UBS. Estimates also cut, given lower growth at a couple of top customers. Neutral rating.
Thomas & Betts
numbers boosted at Oppenheimer. Shares of TNB now seen reaching $71, according to Oppenheimer. Estimates also upped, given better industrial demand and pricing. Outperform rating.
numbers raised at UBS. Shares of WLT now seen reaching $164, according to UBS. Estimates also increased, to adjust for the WTN acquisition.
End of report.
This article was written by a staff member of TheStreet.